Market Signal Briefing

Amazon's plan to invest up to $50 billion in OpenAI could depend on whether the AI developer goes public or achieves artificial general intelligence (AGI), The Information reported on Wednesday, citing people familiar with the matter.

Xperi (XPER - Free Report) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this media software company would post earnings of $0.25 per share when it actually produced earnings of $0.28, delivering a surprise of +12%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Xperi, which belongs to the Zacks Technology Services industry, posted revenues of $116.51 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.14%. This compares to year-ago revenues of $122.36 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Xperi shares have lost about 8% since the beginning of the year versus the S&P 500's gain of 0.7%.

What's Next for Xperi?While Xperi has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Xperi was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.21 on $111.31 million in revenues for the coming quarter and $0.96 on $468.54 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Technology Services is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Cricut, Inc. (CRCT - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 3.

This company is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of -33.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Cricut, Inc.'s revenues are expected to be $198.69 million, down 5.1% from the year-ago quarter.

Xencor (XNCR - Free Report) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +86.00%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.72 per share when it actually produced a loss of $0.08, delivering a surprise of +88.89%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Xencor, which belongs to the Zacks Medical - Drugs industry, posted revenues of $28.24 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 30.62%. This compares to year-ago revenues of $52.79 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Xencor shares have lost about 22.9% since the beginning of the year versus the S&P 500's gain of 0.7%.

What's Next for Xencor?While Xencor has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Xencor was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.66 on $21.13 million in revenues for the coming quarter and -$2.65 on $87.98 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Rigel Pharmaceuticals (RIGL - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 3.

This drug developer is expected to post quarterly earnings of $1.33 per share in its upcoming report, which represents a year-over-year change of +66.3%. The consensus EPS estimate for the quarter has been revised 30.4% higher over the last 30 days to the current level.

Rigel Pharmaceuticals' revenues are expected to be $69.81 million, up 21.2% from the year-ago quarter.

Veracyte (VCYT - Free Report) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +30.06%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.32 per share when it actually produced earnings of $0.51, delivering a surprise of +59.38%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Veracyte, which belongs to the Zacks Medical - Instruments industry, posted revenues of $140.64 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.41%. This compares to year-ago revenues of $118.63 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Veracyte shares have lost about 15.2% since the beginning of the year versus the S&P 500's gain of 0.7%.

What's Next for Veracyte?While Veracyte has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Veracyte was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.34 on $131.36 million in revenues for the coming quarter and $1.61 on $577.29 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Lucid Diagnostics Inc. (LUCD - Free Report) , has yet to report results for the quarter ended December 2025.

This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +63.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Lucid Diagnostics Inc.'s revenues are expected to be $1.3 million, up 8.3% from the year-ago quarter.

TKO Group Holdings (TKO - Free Report) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of $0.14. This compares to earnings of $0.35 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -157.97%. A quarter ago, it was expected that this producer of professional wrestling events and television shows would post earnings of $0.55 per share when it actually produced earnings of $0.5, delivering a surprise of -9.09%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

TKO Group, which belongs to the Zacks Film and Television Production and Distribution industry, posted revenues of $1.04 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.37%. This compares to year-ago revenues of $642.2 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

TKO Group shares have added about 0.2% since the beginning of the year versus the S&P 500's gain of 0.7%.

What's Next for TKO Group?While TKO Group has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for TKO Group was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.23 on $1.73 billion in revenues for the coming quarter and $5.98 on $5.95 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Film and Television Production and Distribution is currently in the bottom 18% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, CuriosityStream Inc. (CURI - Free Report) , is yet to report results for the quarter ended December 2025. The results are expected to be released on March 11.

This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

CuriosityStream Inc.'s revenues are expected to be $18.4 million, up 30.2% from the year-ago quarter.

February 25, 2026 19:57 ET  | Source: Palvella Therapeutics Inc.

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the pricing of its upsized public offering of 1,600,000 shares of its common stock at a price to the public of $125.00 per share. In addition, Palvella has granted the underwriters a 30-day option to purchase up to an additional 240,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Palvella from this offering are expected to be $200 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters’ option to purchase additional shares. All shares of common stock are being offered by Palvella. The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.

TD Cowen, Cantor, Stifel, Mizuho, LifeSci Capital, Oppenheimer & Co., Canaccord Genuity and H.C. Wainwright & Co. are acting as joint bookrunning managers for the offering. Lucid Capital Markets, Jones, Clear Street and Craig-Hallum are acting as co-managers for the offering.

Palvella intends to use the net proceeds from this offering to support the development of its programs, including QTORIN rapamycin and QTORIN pitavastatin, and for working capital and other general corporate purposes, including research and development expenses.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-292544) that was declared effective by the Securities and Exchange Commission (“SEC”) on January 29, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available for free on the SEC’s website at www.sec.gov. A final prospectus supplement with the final terms of the offering and accompanying prospectus will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022 or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364‐2720 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis.

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Palvella’s management. Such forward-looking statements include, without limitation, statements relating to the completion, use of proceeds and anticipated total gross proceeds from the offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering, and other risks and uncertainties related to the public offering, as well as the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Palvella’s periodic reports, including Palvella’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Palvella assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Contact Information:
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
[email protected]

Media:
Marcy Nanus
Managing Partner, Trilon Advisors LLC
[email protected]

Exzeo Group, Inc. (XZO) Q4 2025 Earnings Call February 25, 2026 5:45 PM EST

Company Participants

William Broomall - Vice President of Investor Relations
Suela Bulku - Chief Financial Officer
Kevin Mitchell - President & Director
Pareshbhai Patel - CEO & Chairman

Conference Call Participants

Terrell Tillman - Truist Securities, Inc., Research Division
Dylan Becker - William Blair & Company L.L.C., Research Division
Matthew Carletti - Citizens JMP Securities, LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to Exzeo Group's Fourth Quarter 2025 Earnings Call. My name is Mark, and I will be your conference operator. [Operator Instructions]

Before we begin today's call, I would like to remind everyone that this conference call is being broadcast live via webcast and is available for webcast replay approximately 4 hours after the call through February 25, 2027, on the Investor Relations section of Exzeo Group's website at www.exzeo.com.

I would now like to turn the call over to Bill Broomall, Vice President of Investor Relations. Bill, please proceed.

William Broomall
Vice President of Investor Relations

Thank you, and good afternoon. Welcome to Exzeo Group's Fourth Quarter 2025 Earnings Call. To access today's webcast, please visit the investor information section of our corporate website at www.exzeo.com.

Before we begin, I would like to take the opportunity to remind our listeners that today's presentation and responses to questions may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipate, estimate, expect, intend, plan and project, and other similar words and expressions, are intended to signify forward-looking statements.

Forward-looking statements are not guarantees of future results and conditions, but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company's filings with the Securities and Exchange Commission. Should any risks or uncertainties develop

LOS ANGELES--(BUSINESS WIRE)--Oddity Tech Ltd. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – ODD.

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE:KD) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until April 13, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is the Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of August 7, 2024 through February 9, 2026, inclusive (“the Class Period”). The lawsuit alleges that (1) Kyndryl’s financial statements issued during the Class Period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (3) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.

On February 9, 2026, Kyndryl announced the Company’s CFO and General Counsel had both departed “effective immediately.” The Company also announced that it “is reviewing its cash management practices related disclosures” as well as “the efficacy of the Company’s internal control over financial reporting, and certain other matters following the Company’s receipt of voluntary document requests from the Division of Enforcement of the Securities and Exchange Commission (“SEC”) relating to such matters.” On this news, the price of Kyndryl shares declined by $12.90 per share, or approximately 55%, from $23.49 per share on February 6, 2026 to close at $10.59 on February 9, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Kyndryl securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.

If you currently own DexCom stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Fremont, California--(Newsfile Corp. - February 25, 2026) - Enablence Technologies Inc. (TSXV: ENA) ("Enablence" or the "Company"), a leading supplier of planar lightwave circuit (PLC) optical chips for datacom, telecom, artificial intelligence (AI), and advanced vision applications, today announced the appointment of two seasoned technology executives to its senior management team. Jianhua Hu has been named Fab Director of the Company's Fremont wafer fabrication facility, and Robert Piper has been appointed Chief of Staff to the CEO.

Hu and Piper will play a key role in the execution of Enablence's strategic growth plan, with a focus on operational scaling, equipment onboarding, and capacity expansion at the Company's Fremont fab. Their appointments strengthen Enablence's leadership team as it accelerates manufacturing readiness to meet increasing demand from next-generation data centers and advanced sensing applications. Over the past two years, Enablence has introduced multiple new optical products, expanded strategic technology and manufacturing partnerships, and invested in advanced tooling and materials to enhance operational performance and boost capacity.

"I am pleased to welcome Jianhua and Bob to Enablence at this pivotal stage of our growth plan," said Todd Haugen, CEO of Enablence Technologies. "Jianhua brings deep experience driving operational excellence and consistently improving fab performance. Bob's leadership across global technology organizations will strengthen our execution discipline and operational rigor as we scale to support our expanding commercial opportunities in 2026 and beyond."

Robert Piper, Chief of Staff

Piper brings extensive commercial and operational leadership experience across advanced technology sectors, with a strong track record in supporting high-growth, Fortune 100 organizations. Prior to joining Enablence, he held senior positions at Microsoft, MPIRICA Health Analytics and Oracle, where he guided complex technology organizations through periods of rapid growth and operational transformation.

As Chief of Staff to the CEO, Piper will support global operations, manufacturing execution, and supply chain strategy, helping align cross-functional priorities as the Company scales.

Jianhua Hu, Ph.D., Fab Director

Hu will lead operations at Enablence's Fremont wafer fab and oversee capacity expansion across the Company's growing optical product portfolio. He brings more than 25 years of semiconductor and advanced manufacturing experience spanning semiconductor, solar, LED, and data storage technologies.

Prior to joining Enablence, Hu held fab and operational leadership roles at Western Digital, Applied Materials, Intevac Photonics, OptiSolar, and Tesla. He has extensive experience ramping both startup and established manufacturing organizations both publicly traded and privately held. Hu holds a Ph.D. in Chemistry and an M.A. in Physics from Harvard University, and a B.S. in Chemistry from Wuhan University.

About Enablence Technologies Inc.

Enablence is a publicly traded company listed on the TSX Venture Exchange (TSXV: ENA) that designs, markets, and manufactures optical chips and subsystems based on planar lightwave circuit (PLC) technology. Its silicon-based optical solutions serve datacom, telecom, automotive, and AI-driven applications, with a primary focus on data center markets. The Company also supports emerging applications including medical devices, automotive LiDAR, and virtual and augmented reality systems. Enablence operates a proprietary, non-captive fabrication facility in Fremont, California, which also manufactures chips for select third-party customers.

# # #

Cautionary Note Regarding Forward-Looking Information

This news release contains forward-looking statements regarding the Company based on current expectations and assumptions of management, which involve known and unknown risks and uncertainties associated with our business and the economic environment in which the business operates. All such statements are forward-looking statements under applicable Canadian securities legislation. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. These statements are based on current expectations that involve several risks and uncertainties which could cause actual results to differ from those anticipated. Although the Company believes that the expectations reflected in the forward-looking statements contained in this news release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. We caution our readers of this news release not to place undue reliance on our forward-looking statements as a few factors could cause actual results or conditions to differ materially from current expectations.

Additional information on these and other factors that could affect the Company's operations are set forth in the Company's continuous disclosure documents that can be found on SEDAR+ (www.sedarplus.ca) under Enablence's issuer profile.

Enablence does not intend, and disclaims any obligation, except as required by law, to update or revise any forward-looking statements whether because of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

# # #

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285389

Source: Enablence Technologies Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Live Nation Entertainment, Inc. (NYSE: LYV) breached their fiduciary duties to shareholders.

If you currently own Live Nation stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of WEBTOON Entertainment Inc. (NASDAQ: WBTN) breached their fiduciary duties to shareholders.

If you currently own WEBTOON stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected] 
[email protected] 
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of SolarEdge Technologies, Inc. (NASDAQ: SEDG) breached their fiduciary duties to shareholders.

If you currently own SolarEdge stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public.

So What: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=52527 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On February 3, 2026, a post was issued on Stockwits in which it stated that "GSI is almost certainly hiding that their chip did not run Gemma-3 at all, only the pre-generation RAG phase. APU lack the MAC units required for matrix multiplication, which is critical for AI workloads."

On this news, GSI Technology's stock price fell $1.08 per share, or 14.2%, to close at $6.52 per share on February 4, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

TORONTO--(BUSINESS WIRE)--RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) today announced that it has agreed to issue $200 million principal amount of Series AQ senior unsecured debentures (the “Debentures”). The Debentures will be sold at a price of $100 per $100 principal amount, carry a coupon of 4.308% per annum and will mature on March 11, 2033. The net proceeds of the Debentures being offered will be used by the Trust to repay existing indebtedness at or prior.

New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026.

SO WHAT: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Enphase overstated its ability to manage its channel inventory; (2) Enphase overstated its ability to mitigate effects arising from the termination of the Residential Clean Energy Credit; (3) accordingly, Enphase overstated its financial and operational prospects; and (4) as a result, Enphase's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285378

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SentinelOne (S - Free Report) ended the recent trading session at $12.92, demonstrating a +1.25% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.81%. On the other hand, the Dow registered a gain of 0.63%, and the technology-centric Nasdaq increased by 1.26%.

The cybersecurity provider's stock has dropped by 15.55% in the past month, falling short of the Computer and Technology sector's loss of 2.23% and the S&P 500's loss of 0.25%.

The upcoming earnings release of SentinelOne will be of great interest to investors. The company's earnings report is expected on March 12, 2026. On that day, SentinelOne is projected to report earnings of $0.06 per share, which would represent year-over-year growth of 50%. Meanwhile, our latest consensus estimate is calling for revenue of $270.96 million, up 20.15% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $0.19 per share and a revenue of $1 billion, demonstrating changes of +280% and +21.86%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for SentinelOne. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, SentinelOne boasts a Zacks Rank of #3 (Hold).

With respect to valuation, SentinelOne is currently being traded at a Forward P/E ratio of 43.89. This denotes a premium relative to the industry average Forward P/E of 38.

The Security industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 176, positioning it in the bottom 29% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow S in the coming trading sessions, be sure to utilize Zacks.com.

C3.ai logo is seen in this illustration taken February 16, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

Feb 25 (Reuters) - Software provider C3.ai (AI.N), opens new tab said it is cutting 26% of its global workforce as part of a restructuring push under new CEO Stephen Ehikian, and also forecast current-quarter sales below estimates, sending its shares down 20% in extended trading.

The company, which had roughly 1,181 full-time employees as of April 30, 2025, said on Wednesday it expected to record about $10 million to $12 million in restructuring charges this quarter, and aims to cut non-wages-related costs by around 30% by late 2027.

Get a daily digest of breaking business news straight to your inbox with the Reuters Business newsletter. Sign up here.

For the third quarter, C3.ai's adjusted net loss per share of 40 cents came in wider than analysts' average estimate of a loss of 29 cents, according to data compiled by LSEG.

"It was clear to me that we were not organized appropriately. We've reduced our cost structure and cash burn. We've restructured and flattened the sales organization," Ehikian, who took charge in September, said in a statement.

It expects fourth-quarter revenue between $48 million and $52 million, sharply lower than estimates of $77.47 million.

C3.ai projected annual adjusted loss from operations of about $219.5 million to $227.5 million, compared with a loss of $324.4 million reported in fiscal 2025.

Reporting by Juveria Tabassum in Bengaluru; Editing by Sherry Jacob-Phillips

Our Standards: The Thomson Reuters Trust Principles., opens new tab

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026.

SO WHAT: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Enphase overstated its ability to manage its channel inventory; (2) Enphase overstated its ability to mitigate effects arising from the termination of the Residential Clean Energy Credit; (3) accordingly, Enphase overstated its financial and operational prospects; and (4) as a result, Enphase’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NerdWallet, Inc. (NRDS) Q4 2025 Earnings Call Transcript

OUTFRONT Media Inc. (OUT) Q4 2025 Earnings Call Transcript

, /PRNewswire/ -- Omnicom (NYSE: OMC) today announced the pricing of its public offerings of (i) $1.7 billion aggregate principal amount of senior notes (collectively, the "USD Notes") to be issued by Omnicom and (ii) €600 million aggregate principal amount of senior notes to be issued by Omnicom Finance Holdings plc (the "Euro Notes Issuer"), a wholly owned indirect subsidiary of Omnicom, which Euro Notes (as defined below) will be fully and unconditionally guaranteed by Omnicom. The offerings are comprised of the following tranches:

$400 million aggregate principal amount of 4.200% Senior Notes due 2029 (the "2029 Notes"); $700 million aggregate principal amount of 5.000% Senior Notes due 2033 (the "2033 Notes"); $600 million aggregate principal amount of 5.300% Senior Notes due 2036 (the "2036 Notes"); and €600 million aggregate principal amount of 3.850% Senior Notes due 2034 (the "Euro Notes"). The offerings are expected to close on March 2, 2026, subject to the satisfaction of customary closing conditions. The offerings are not conditioned on each other.

The USD Notes Offering
The 2029 Notes, 2033 Notes and the 2036 Notes will mature on March 2, 2029, June 2, 2033 and June 2, 2036, respectively. The USD Notes will be the unsecured and unsubordinated obligations of Omnicom and will rank equal in right of payment to all its existing and future unsecured senior indebtedness.

The USD Notes will not be listed on any securities exchange or included in any automated quotation system.

Omnicom intends to use the net proceeds from the USD Notes offering to fund the repayment of its 3.600% Senior Notes due 2026 co-issued with Omnicom Capital Inc., which mature on April 15, 2026, of which $1.4 billion aggregate principal amount was outstanding as of December 31, 2025, and any remaining proceeds for general corporate purposes, which could include working capital expenditures, fixed asset expenditures, acquisitions, repayment of commercial paper and short-term debt, refinancing of other debt, repurchases of Omnicom's common stock or other capital transactions.

Citigroup Global Markets Inc. and Deutsche Bank Securities Inc. are acting as joint global coordinators and joint book-running managers and BofA Securities, Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the USD Notes offering.

The Euro Notes Offering
The Euro Notes will mature on May 2, 2034. The Euro Notes will be fully and unconditionally guaranteed by Omnicom. The Euro Notes and the related guarantee will be the unsecured and unsubordinated obligations of the Euro Notes Issuer and Omnicom, respectively, and will rank equal in right of payment to all of their respective existing and future unsecured senior indebtedness.

A listing application will be made to have the Euro Notes listed on The New York Stock Exchange, which will be subject to approval by The New York Stock Exchange. If such a listing is obtained, the Euro Notes Issuer will have no obligation to maintain such listing, and the Euro Notes Issuer may delist the Euro Notes at any time.

The Euro Notes Issuer intends to use the net proceeds from the Euro Notes offering for general corporate purposes, which could include working capital expenditures, fixed asset expenditures, acquisitions, repayment of commercial paper and short-term debt, refinancing of other debt, repurchases of Omnicom's common stock or other capital transactions.

Citigroup Global Markets Limited and Deutsche Bank AG, London Branch are acting as joint global coordinators and joint book-running managers and BNP PARIBAS and HSBC Bank plc are acting as joint book-running managers for the Euro Notes offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make an offer, solicitation or sale in such jurisdiction. The public offerings are being made pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission ("SEC"). A final prospectus supplement related to the Euro Notes offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. In addition, copies of the prospectus and prospectus supplement relating to the Euro Notes offered in the Euro Notes offering may be obtained by contacting any of the following underwriters: Citigroup Global Markets Limited at 1-800-831-9146, Deutsche Bank AG, London Branch at 1-800-503-4611, BNP PARIBAS at 1-800-854-5674 and HSBC Bank plc at 1-866-811-8049. A separate final prospectus supplement related to the USD Notes offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. In addition, copies of the prospectus and prospectus supplement relating to the USD Notes offered in the USD Notes offering may be obtained by contacting any of the following underwriters: Citigroup Global Markets Inc. at 1-800-831-9146, Deutsche Bank Securities Inc. at +1-800-503-4611, BofA Securities, Inc. at 201 North Tryon Street, NC1-022-02-25, Charlotte, NC 28255-0001, Attn: Prospectus Department or toll-free at 1-800-294-1322 or by email at [email protected], J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected] and Wells Fargo Securities, LLC at 1-800-645-3751.

MIFID II AND UK MIFIR PRODUCT GOVERNANCE / PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY TARGET MARKET / NO PRIIPs KID OR UK PRIIPs KID — Manufacturer target market is eligible counterparties and professional clients only (all distribution channels). No key information document ("KID") under Regulation (EU) No. 1286/2014 (as amended, the "PRIIPs Regulation") or PRIIPS Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA") (the "UK PRIIPs Regulation") has been prepared as the notes are not available to retail investors in a member state of the European Economic Area (the "EEA") or the United Kingdom ("UK").

In the EEA, the notes offered are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129, as amended or superseded. Consequently, no KID required by the PRIIPs Regulation, for offering or selling the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

In the UK, the notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the UK. For these purposes, a retail investor means a person who is neither: (i) a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA (the "UK MiFIR"); nor (ii) a qualified investor as defined in paragraph 15 of Schedule 1 to The Public Offers and Admissions to Trading Regulations 2024. Consequently, no KID required by the UK PRIIPs Regulation for offering or selling the notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

In the UK, this press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the UK, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.

About Omnicom
Omnicom (NYSE: OMC) is the world's leading marketing and sales company, built for intelligent growth in the next era. Powered by Omni, Omnicom's Connected Capabilities unite the company's world‑class agency brands, exceptional talent, and deep domain expertise across media, commerce, consulting, precision marketing, advertising, production, health, public relations, branding, and experiential to address clients' most critical growth priorities.

Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements, including statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In addition, from time to time, Omnicom or its representatives have made, or may make, forward-looking statements, orally or in writing. These statements, other than statements of historical fact, may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of Omnicom's management as well as assumptions made by, and information currently available to, Omnicom's management. Forward-looking statements may be accompanied by words such as "aim," "anticipate," "believe," "plan," "could," "should," "would," "estimate," "expect," "forecast," "future," "guidance," "intend," "may," "will," "possible," "potential," "predict," "project" or similar words, phrases or expressions. These forward-looking statements are subject to various risks and uncertainties, many of which are outside Omnicom's control. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include:

risks relating to the completed merger (the "Merger") between Omnicom and The Interpublic Group of Companies, Inc. ("IPG"), including risks related to the integration of IPG's business, such as, among others: uncertainties associated with retaining key management and other employees; potential disruptions to client, vendor, and business partner relationships; the risk that integration activities may be more time-consuming, complex, or costly than expected; the possibility that anticipated synergies, efficiencies, and other benefits of the Merger may not be realized, or may be realized more slowly than anticipated; and risks associated with managing a larger, more complex combined organization and effectively integrating systems, processes, operations, and cultures; adverse economic conditions, including geopolitical events, international hostilities, acts of terrorism, public health crises, inflation or stagflation, tariffs and other trade barriers, central bank interest rate policies in countries that comprise Omnicom's major markets, labor and supply chain issues affecting the distribution of Omnicom's clients' products, or a disruption in the credit markets; international, national or local economic conditions that could adversely affect Omnicom or its clients; reductions in client spending, a slowdown in client payments or a deterioration or disruption in the credit markets; the ability to attract new clients and retain existing clients in the manner anticipated; changes in client marketing and communications services requirements; failure to manage potential conflicts of interest between or among clients; unanticipated changes related to competitive factors in the marketing and communications services industries; unanticipated changes to, or an inability to hire and retain key personnel; currency exchange rate fluctuations; reliance on information technology systems and risks related to cybersecurity incidents; effective management of the risks, challenges and efficiencies presented by utilizing artificial intelligence, or AI, technologies and related partnerships in Omnicom's business, and their use by Omnicom's competitors; failure to adapt to technological developments; Omnicom's liquidity, long-term financing needs, credit ratings and access to capital markets; changes in legislation or governmental regulations affecting Omnicom or its clients; losses on media purchases and production costs incurred on behalf of clients; risks associated with assumptions Omnicom makes in connection with Omnicom's acquisitions, critical accounting estimates and legal proceedings; Omnicom's international operations, which are subject to the risks of currency repatriation restrictions, social or political conditions and an evolving regulatory environment in high-growth markets and developing countries; risks related to Omnicom's environmental, social and governance goals and initiatives, including impacts from regulators and other stakeholders, and the impact of factors outside of Omnicom's control on such goals and initiatives; changes in tax rates, tax laws, regulations or interpretations, or adverse outcomes of tax audits or proceedings; and other business, financial, operational and legal risks and uncertainties detailed from time to time in Omnicom's SEC filings. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that may affect Omnicom's business, including those described in Item 1A, "Risk Factors" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Omnicom's Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents filed from time to time with the SEC. Except as required under applicable law, Omnicom does not assume any obligation to update these forward-looking statements.

SOURCE Omnicom Group Inc.